Monitoring Agency Report for the quarter ended March 31, 2026, for Rights Issue.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
India Ratings & Research, the monitoring agency, has confirmed that Camlin Fine Sciences fully utilized the ₹22,468.39 Lakhs raised through its Rights Issue (January 2025) with no deviations from the stated objects. The issue comprised 2.04 crore equity shares at ₹110 each, though 439 shares were kept in abeyance reducing proceeds by ₹0.48 Lakhs. Funds were deployed across three heads: repayment of borrowings (₹16,904.93 Lakhs), general corporate purposes (₹5,494.22 Lakhs), and issue expenses (₹69.24 Lakhs). The company reallocated ₹129.50 Lakhs of unspent issue expenses to general corporate purposes since those costs were incurred before receiving issue proceeds. This is the final monitoring report, confirming 100% utilization as of March 31, 2026.
Positive for shareholders — the rights issue proceeds have been fully and appropriately deployed as promised, with independent auditor and monitoring agency confirmation of no misuse of funds.